In addition, Sasaki et al. recently reported that 6% (3/50) of treatment-naïve NSCLC patients with ALK rearrangement had concurrent EGFR activating mutations and that the ALK rearrangement was inactive in these patients due to EGFR mutation [23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.